公开(公告)号：WO2007133746A2

公开(公告)日：2007-11-22

申请号：PCT/US2007011557

申请日：2007-05-15

Applicant: BIOGEN IDEC INC ,  RELTON JANE K ,  LI MINGWEI ,  JI BENXIU

Inventor： RELTON JANE K ,  LI MINGWEI ,  JI BENXIU

IPC: A61M5/32

CPC classification number: C07K14/705 ,  A61K38/00

Abstract: The invention provides methods of treating diseases, disorsers or injuries involving oligodendrocyte death, demyelination and dysmyelination, including spinal cord injury, by the administration of an NgR1 antagonist.

Abstract translation: 本发明提供了通过施用NgR1拮抗剂治疗涉及少突胶质细胞死亡，脱髓鞘和脱髓鞘疾病（包括脊髓损伤）的疾病，脱发剂或损伤的方法。

公开(公告)号：WO0041545A3

公开(公告)日：2000-09-28

申请号：PCT/US0000873

申请日：2000-01-13

Applicant: ONTOGENY INC ,  DUDEK HENRYK ,  JI BENXIU

Inventor： DUDEK HENRYK ,  JI BENXIU

IPC: C12N5/06 ,  A61K20060101 ,  A61K8/00 ,  A61K8/63 ,  A61K31/00 ,  A61K31/13 ,  A61K31/335 ,  A61K31/35 ,  A61K31/352 ,  A61K31/4747 ,  A61K31/56 ,  A61K31/58 ,  A61K31/585 ,  A61K31/695 ,  A61K31/70 ,  A61K45/00 ,  A61P1/16 ,  A61P7/00 ,  A61P9/00 ,  A61P15/16 ,  A61P17/00 ,  A61P17/06 ,  A61P19/08 ,  A61P21/00 ,  A61P25/00 ,  A61P35/00 ,  A61P43/00 ,  A61Q5/00 ,  A61Q7/00 ,  A61Q19/00 ,  C07J69/00 ,  C12N15/00 ,  G01N33/483 ,  G01N33/50 ,  G01N33/574

CPC classification number: A61K31/585 ,  A61K31/35 ,  A61K31/56 ,  A61K31/58 ,  A61K31/70 ,  Y10S514/863

Abstract: The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting a cell with a compound, such as a polypeptide or small molecule in an amount sufficient to control the aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity. The present invention further makes available methods and reagents for ameliorating the consequences of hedgehog loss-of-function, ptc gain-of-function, or smoothened loss-of-function comprising contacting a cell with a compound, such as a polypeptide or small molecule, in an amount sufficient for amelioration. In certain embodiments, the subject compounds, e.g., a cAMP analog, adenylate cyclase agonist, or cAMP phosphodiesterase inhibitor, regulate cAMP levels, which in turn modulates activity of the hedgehog pathway.

Abstract translation: 本发明提供用于抑制由刺猬获得功能，功能丧失功能或平滑增益功能引起的异常生长状态的可用方法和试剂，包括使细胞与化合物如多肽或小分子接触 其量足以控制异常生长状态，例如，激发正常的ptc途径或拮抗平滑或刺猬活性。 本发明进一步提供用于改善hedgehog功能丧失功能，ptc功能增益或平滑功能丧失的后果的可用方法和试剂，包括使细胞与化合物如多肽或小分子接触 ，其量足以改善。 在某些实施方案中，主题化合物，例如cAMP类似物，腺苷酸环化酶激动剂或cAMP磷酸二酯酶抑制剂调节cAMP水平，其依次调节刺猬蛋白通路的活性。

公开(公告)号：WO2007133746A3

公开(公告)日：2007-11-22

申请号：PCT/US2007/011557

申请日：2007-05-15

Applicant: BIOGEN IDEC MA INC. ,  RELTON, Jane, K. ,  LI, Mingwei ,  JI, Benxiu

Inventor： RELTON, Jane, K. ,  LI, Mingwei ,  JI, Benxiu

IPC: A01N61/00 ,  A01N37/18 ,  A61K49/00

Abstract: The invention provides methods of treating diseases, disorsers or injuries involving oligodendrocyte death, demyelination and dysmyelination, including spinal cord injury, by the administration of an NgR1 antagonist.